Maker of Ozempic, Wegovy sues Minnesota clinic over knockoff weight-loss medication
Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 drugs.
Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in early trial
The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new chapter in Big Pharma’s billion-dollar war on obesity, as Novo Nordisk and Eli Lilly battle it out over the latest blockbuster drugs.
Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.
Novo Nordisk hails ‘remarkable’ weight loss result for dual-acting oral drug in early trial
Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for further reductions in longer trials.
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in trial
Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects.
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Experimental Weight Loss Drug Beat Ozempic and Wegovy in Early Trial
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.
This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Hims & Hers to Offer Weight Loss Medication for Workers in Specific Professions
There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...
‘Dual-action’ weight-loss pill helps people drop 13% of body weight in three months in early trials
An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...
NBC New York8d
Novo Nordisk weight-loss drug is effective for kids as young as 6, study shows
The new study, paid for by Novo Nordisk, included 82 children with a mean age of 10 and a baseline weight of about 155 ...
GLP-1 pills are coming, and they could revolutionize weight-loss treatment
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.